Non-small Cell Lung Cancer Market expected to rise | Companies – GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer, F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals

Non-small Cell Lung Cancer Market

The Non-small Cell Lung Cancer market growth is driven by factors like increase in the prevalence of Non-small Cell Lung Cancer, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Non-small Cell Lung Cancer market report also offers comprehensive insights into the Non-small Cell Lung Cancer market size, share, Non-small Cell Lung Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Non-small Cell Lung Cancer market size growth forward. 

Some of the key highlights from the Non-small Cell Lung Cancer Market Insights Report:

• Several key pharmaceutical companies, including GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer, F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, and others, are developing novel products to improve the Non-small Cell Lung Cancer treatment outlook. 
• The total Non-small Cell Lung Cancer market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
• As per DelveInsight analysis, the Non-small Cell Lung Cancer market is anticipated to witness growth at a considerable CAGR
• Non-small Cell Lung Cancer market size has seen a revolutionary change in the last decade owing to the increase in incident cases of NSCLC, continuous uptake of approved therapies mainly immune checkpoint inhibitors, expected entry of potential premium price emerging therapies and increasing awareness of mutations like KRAS, BRAF, c-Met, and others.
• The real-world treatment trend depicts a drastic shift towards targeted and immunotherapies (from only systemic therapies in the past), which is expected to contribute the most now.
• The existing Non-small Cell Lung Cancer treatment is mainly dominated by targeted therapies for mutations such as EGFR-sensitizing mutations, EGFR exon 20 insertions, ALK fusions, ROS1 fusions, BRAFV600E mutation, MET exon 14 skipping mutations, RET fusions, and KRASG12C mutation.
• Amgen’s LUMAKRAS monotherapy is approved in 2021 for NSCLC patients harboring KRASG12C mutation. It is expected to reach approximately USD 400 million in first-line setting (mono and combo with Keytruda/Tecentriq), and approximately USD 800 million in relapsed refractory setting in the United States.
• Throwing some light on adjuvant and neo-adjuvant NSCLC market trends, the entry of immunotherapies such as TECENTRIQ and OPDIVO has been witnessed in the last 2-3 years
• As far as EGFR-positive NSCLC market size is concerned, we expect third-generation EGFRs such as AstraZeneca’s TAGRISSO to dominate
• As per DelveInsight’s analysis, the total incident cases of NSCLC in the 7MM were approximately 500,000 cases in the year 2022 which is expected to reach approximately 600,000 cases in the year 2032.
• The most common alteration seen in Non–Small Cell Lung Cancer is EGFR mutation. This occurs in about 20–25% of patients, and EGFR mutations occur in exon 19—that’s a deletion—as well as L858R exon 21. This makes up about 80–85% of all EGFR mutations.
• Other emerging therapies include AbbVie’s Telisotuzumab Vedotin, Sanofi’s SAR408701, and AstraZeneca and Daiichi Sankyo’s Datopotamab deruxtecan, which have the potential to create a significant positive shift in the Non-small Cell Lung Cancer market size.

Strategise your business goals by understanding market dynamics @ Non-small Cell Lung Cancer Market Landscape

Non-small Cell Lung Cancer Overview 

Non-small Cell Lung Cancer is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. Early diagnosis offers the best prognosis for Non–Small Cell Lung Cancer. But, Non–Small Cell Lung Cancer and other lung cancers can be difficult to diagnose because, often, these cancers have symptoms that are mistaken for common illnesses or the effects of long-term smoking. Because of this, 80 percent of people diagnosed with Non–Small Cell Lung Cancer have already progressed to advanced stages, making it more difficult to treat. If lung cancer is suspected, the physician will recommend imaging tests (CT, PET, or MRI scans) to identify abnormalities in and around your lungs. The physician may also take a sample of mucus for examination under the microscope.

If these initial tests identify cancer, a lung biopsy can be conducted. A bronchoscopy can also be recommended, which allows the physician to not only visualize but also remove tissue. If lung cancer is confirmed, genetic testing can be done on the lung tissue to identify details about the cancer that can help inform treatment.

Non-small Cell Lung Cancer Treatment

Treatment options and recommendations depend on several factors, including the type and stage of cancer, possible side effects, and the patient’s preferences and overall health. The most common treatments for non-small cell lung cancer are:

• surgery
• radiotherapy
• chemotherapy
• chemotherapy with radiotherapy (chemoradiotherapy)
• immunotherapy
• targeted cancer drugs

Do you know the treatment paradigms for different countries? Download our Non-small Cell Lung Cancer Market Sample Report

Recent Breakthroughs in the Non-small Cell Lung Cancer Market

Zenocutuzumab Wins FDA Breakthrough Therapy Designation for Advanced NRG1+ NSCLC: 

The FDA has granted breakthrough therapy designation to zenocutuzumab (MCLA-128) for use as a potential therapeutic option in patients with advanced unresectable or metastatic, NRG1 fusion–positive non–small cell lung cancer (NSCLC) following progression with prior systemic therapy.

Non-small Cell Lung Cancer Epidemiology Insights

• In the US for 2023, there are approximately 200,000 new cases of lung cancer (117,550 in men and 120,790 in women). The society also reported that most lung cancer statistics include both small cell lung cancer and non-small cell lung cancer. About 10% to 15% of all lung cancers are SCLC, and about 80% to 85% are Non–Small Cell Lung Cancer.
• The most frequent biomarkers are EGFR (64%), ALK (60%), PD-L1 (48%), ROS1 (46%), BRAF (40%), MET (35%), KRAS (29%), RET (22%), HER2 (21%), and PIK3CA (20%).
• The three main histological subtypes of Non–Small Cell Lung Cancer are Adenocarcinoma, Squamous cell carcinoma, and Large cell (undifferentiated) carcinoma. About 40% of all lung cancers are adenocarcinomas. About 25-30% of all lung cancers are Squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 10-15% of all lung cancers.

Non-small Cell Lung Cancer Epidemiology Segmentation 

DelveInsight’s Non-small Cell Lung Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Non-small Cell Lung Cancer historical patient pools and forecasted Non-small Cell Lung Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Non-small Cell Lung Cancer Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Non-small Cell Lung Cancer Prevalence 
• Age-Specific Non-small Cell Lung Cancer Prevalence 
• Gender-Specific Non-small Cell Lung Cancer Prevalence 
• Diagnosed and Treatable Cases of Non-small Cell Lung Cancer

Visit for more @ Non-small Cell Lung Cancer Epidemiological Insights

Clinical and Registrational Updates in 2023

• The US FDA approval of Merck’s KEYTRUDA (pembrolizumab) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
• NDA acceptance of repotrectinib, for the treatment of patients with ROS1-positive locally advanced or metastatic NSCLC. The FDA granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 27, 2023.
• In January 2023, Daiichi Sankyo initiated the TROPION-Lung07 Phase III trial to evaluate datopotamab deruxtecan in combination with pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
• In January 2023, the EMA validated the ENHERTU Type II variation application for the treatment of HER2 mutant metastatic non-small cell lung cancer.

Non–Small Cell Lung Cancer Market Outlook

As more targetable mutations are discovered and new targeted drugs are developed, patients and oncologists will have an expanding array of treatment options. Given the rapid pace of drug approvals, it is important to pause and ensure that there is sufficient data supporting the use of specific agents in the appropriate treatment settings, including adjuvant, consolidation, first-line, or subsequent therapy.

Previously, molecular-based treatments were limited to advanced-stage Non-small Cell Lung Cancer. However, recent findings have demonstrated their efficacy in early-stage and locally advanced disease as well. New studies have explored therapies that target a wider range of oncogenes, aiming to overcome drug resistance and provide treatment options for patients who were previously excluded from Non-small Cell Lung Cancer clinical trials for advanced-stage lung cancer. The emerging data from these ongoing trials are expected to influence future treatment guidelines and foster the adoption of personalized medicine. As a result, a continuous evolution of the treatment landscape is anticipated, ultimately leading to improved survival rates and enhanced quality of life for lung cancer patients.

Non–Small Cell Lung Cancer Companies such as AstraZeneca, Bristol-Myers-Squibb, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda, Eli Lilly, Immutep, Sanofi, GlaxoSmithKline, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Non–Small Cell Lung Cancer.

Non-small Cell Lung Cancer Emerging Therapy Assessment

Telisotuzumab Vedotin (Teliso-V): AbbVie

Teliso-V is an investigational antibody-drug conjugate targeting c-Met, a receptor tyrosine kinase that is overexpressed in tumors including Non-small Cell Lung Cancer. Teliso-V has the potential to become an important new treatment option in non-small cell lung cancer; with an anticipated approval in 2L+ Non–Small Cell Lung Cancer in 2024. In January 2022, AbbVie announced that the FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin for the treatment of patients with advanced/ metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy. In May 2022, AbbVie initiated a Phase III clinical trial to evaluate Teliso-V versus docetaxel for the treatment of patients with previously treated c-Met overexpressing, epidermal growth factor receptor wild type, advanced/metastatic non-squamous non-small cell lung cancer.

Datopotamab deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of the most advanced programs in AstraZeneca’s ADC scientific platform and one of the three leading ADCs in the oncology pipeline of Daiichi Sankyo. In January 2023, a Phase III clinical trial in combination with immune checkpoint inhibitors for the first-line treatment for Non–Small Cell Lung Cancer without actionable genomic alterations, PD-L1 < 50% (trial name: TROPION-Lung07) was initiated. No TROP2-directed therapies are currently approved for the treatment of patients with Non–Small Cell Lung Cancer. AstraZeneca and Daiichi Sankyo are interrogating Dato-DXd in 1L non-driver mutation patients with TROPION-Lung08 (trying to knock off the Keynote-024 regimen) and with TROPION-Lung07 (trying to dethrone Keynote-189 regimen, the most important indication for Merck’s KEYRTUDA), as well as covering all comer 2L and 3L patients in with TROPION-Lung01.

Non-small Cell Lung Cancer Key Companies

• GlaxoSmithKline
• Novartis
• AstraZeneca
• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck
• Millennium Pharmaceuticals, Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Bristol Myers Squibb
• Sanofi
• IO Biotech
• Transgene
• Immutep S.A.
• Daiichi Sankyo, Inc.
• Regeneron Pharmaceuticals
• Hanmi Pharmaceutical Company Limited
• TYK Medicines, Inc

For more information, visit Non-small Cell Lung Cancer Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Non-small Cell Lung Cancer Market Report:

• 10 Years Forecast
• 7MM Coverage 
• Descriptive overview of Non-small Cell Lung Cancer, causes, signs and symptoms, diagnosis, treatment
• Comprehensive insight into Non-small Cell Lung Cancer epidemiology in the 7MM
• Non-small Cell Lung Cancer marketed and emerging therapies 
• Non-small Cell Lung Cancer companies
• Non-small Cell Lung Cancer market drivers and barriers 

Key Questions Answered in the Non-small Cell Lung Cancer Market Report 2032:

• What was the Non-small Cell Lung Cancer market share distribution in 2019, and how would it appear in 2032?
• What is the total Non-small Cell Lung Cancer market size and the market size by therapy across the 7MM for the study period (2019-32)?
• What are the important findings from 7MM, and which country will have the greatest Non-small Cell Lung Cancer market size from 2019-32?
• During the study period (2019-2032), at what CAGR is the Non-small Cell Lung Cancer market projected to expand at 7MM?

Table of Contents:

1 Non-small Cell Lung Cancer Market Key Comprehensive Insights 

2 Non-small Cell Lung Cancer Market Report Introduction

3 Competitive Intelligence Analysis for Non-small Cell Lung Cancer

4 Non-small Cell Lung Cancer Market Analysis Overview at a Glance

5 Executive Summary of Non-small Cell Lung Cancer

6 Non-small Cell Lung Cancer Epidemiology and Market Methodology

7 Non-small Cell Lung Cancer Epidemiology and Patient Population

8 Non-small Cell Lung Cancer Patient Journey

9 Non-small Cell Lung Cancer Treatment Algorithm, Non-small Cell Lung Cancer Current Treatment, and Medical Practices

10 Key Endpoints in Non-small Cell Lung Cancer Clinical Trials

11 Non-small Cell Lung Cancer Marketed Therapies 

12 Non-small Cell Lung Cancer Emerging Therapies

13 Non-small Cell Lung Cancer: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Non-small Cell Lung Cancer

16 Non-small Cell Lung Cancer Market Key Opinion Leaders Reviews

18 Non-small Cell Lung Cancer Market Drivers

19 Non-small Cell Lung Cancer Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Non-small Cell Lung Cancer Epidemiology 2032

DelveInsight’s “Non-small Cell Lung Cancer – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Non-small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Non-small Cell Lung Cancer Pipeline 2023

“Non-small Cell Lung Cancer Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-small Cell Lung Cancer market. A detailed picture of the Non-small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Non-small Cell Lung Cancer treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/